De Jager R - Search Results

1

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.

Verschraegen CF, Kudelka AP, Hu W, Vincent M, Kavanagh JJ, Loyer E, Bastien L, Duggal A, De Jager R. Verschraegen CF, et al. Among authors: de jager r. Cancer Chemother Pharmacol. 2004 Jan;53(1):1-7. doi: 10.1007/s00280-003-0696-7. Epub 2003 Oct 28. Cancer Chemother Pharmacol. 2004. PMID: 14586557 Clinical Trial.

2

A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.

Esteva FJ, Rivera E, Cristofanilli M, Valero V, Royce M, Duggal A, Colucci P, DeJager R, Hortobagyi GN. Esteva FJ, et al. Cancer. 2003 Sep 1;98(5):900-7. doi: 10.1002/cncr.11557. Cancer. 2003. PMID: 12942555 Free article. Clinical Trial.

3

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum.

Royce ME, Rowinsky EK, Hoff PM, Coyle J, DeJager R, Pazdur R, Saltz LB. Royce ME, et al. Invest New Drugs. 2004 Jan;22(1):53-61. doi: 10.1023/b:drug.0000006174.87869.6b. Invest New Drugs. 2004. PMID: 14707494 Clinical Trial.

4

Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.

Royce ME, Hoff PM, Dumas P, Lassere Y, Lee JJ, Coyle J, Ducharme MP, De Jager R, Pazdur R. Royce ME, et al. Among authors: de jager r. J Clin Oncol. 2001 Mar 1;19(5):1493-500. doi: 10.1200/JCO.2001.19.5.1493. J Clin Oncol. 2001. PMID: 11230496 Clinical Trial.

5

Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.

Giles FJ, Cortes JE, Thomas DA, Garcia-Manero G, Faderl S, Jeha S, De Jager RL, Kantarjian HM. Giles FJ, et al. Clin Cancer Res. 2002 Jul;8(7):2134-41. Clin Cancer Res. 2002. PMID: 12114413 Clinical Trial.

6

A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer.

Ajani JA, Takimoto C, Becerra CR, Silva A, Baez L, Cohn A, Major P, Kamida M, Feit K, De Jager R. Ajani JA, et al. Among authors: de jager r. Invest New Drugs. 2005 Oct;23(5):479-84. doi: 10.1007/s10637-005-2907-z. Invest New Drugs. 2005. PMID: 16133799 Clinical Trial.

7

Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy.

Patel S, Keohan ML, Saif MW, Rushing D, Baez L, Feit K, DeJager R, Anderson S. Patel S, et al. Cancer. 2006 Dec 15;107(12):2881-7. doi: 10.1002/cncr.22334. Cancer. 2006. PMID: 17109446 Free article. Clinical Trial.

8

Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.

Sharma S, Kemeny N, Schwartz GK, Kelsen D, O'Reilly E, Ilson D, Coyle J, De Jager RL, Ducharme MP, Kleban S, Hollywood E, Saltz LB. Sharma S, et al. Among authors: de jager rl. Clin Cancer Res. 2001 Dec;7(12):3963-70. Clin Cancer Res. 2001. PMID: 11751488 Clinical Trial.

9

A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.

Garrison MA, Hammond LA, Geyer CE Jr, Schwartz G, Tolcher AW, Smetzer L, Figueroa JA, Ducharme M, Coyle J, Takimoto CH, De Jager RL, Rowinsky EK. Garrison MA, et al. Clin Cancer Res. 2003 Jul;9(7):2527-37. Clin Cancer Res. 2003. PMID: 12855627 Clinical Trial.

10

DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.

Rowinsky EK, Johnson TR, Geyer CE Jr, Hammond LA, Eckhardt SG, Drengler R, Smetzer L, Coyle J, Rizzo J, Schwartz G, Tolcher A, Von Hoff DD, De Jager RL. Rowinsky EK, et al. Among authors: de jager rl. J Clin Oncol. 2000 Sep;18(17):3151-63. doi: 10.1200/JCO.2000.18.17.3151. J Clin Oncol. 2000. PMID: 10963644 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

75 results

Search Page

Filters